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Abstract
Background:  CART (cocaine- and amphetamine-regulated transcript) peptide and
cholecystokinin (CCK) are neuromodulators involved in feeding behavior. This study is based on
previously found synergistic effect of leptin and CCK on food intake and our hypothesis on a co-
operation of the CART peptide and CCK in food intake regulation and Fos activation in their
common targets, the nucleus tractus solitarii of the brainstem (NTS), the paraventricular nucleus
(PVN), and the dorsomedial nucleus (DMH) of the hypothalamus.
Results: In fasted C57BL/6 mice, the anorexigenic effect of CART(61-102) in the doses of 0.1 or
0.5 μg/mouse was significantly enhanced by low doses of CCK-8 of 0.4 or 4 μg/kg, while 1 mg/kg
dose of CCK-A receptor antagonist devazepide blocked the effect of CART(61-102) on food
intake. After simultaneous administration of 0.1 μg/mouse CART(61-102) and of 4 μg/kg of CCK-
8, the number of Fos-positive neurons in NTS, PVN, and DMH was significantly higher than after
administration of each particular peptide. Besides, CART(61-102) and CCK-8 showed an additive
effect on inhibition of the locomotor activity of mice in an open field test.
Conclusion: The synergistic and long-lasting effect of the CART peptide and CCK on food intake
and their additive effect on Fos immunoreactivity in their common targets suggest a co-operative
action of CART peptide and CCK which could be related to synergistic effect of leptin on CCK
satiety.
Background
Information on the metabolic status of the organism
enters and is processed in the hypothalamus and in the
nucleus tractus solitarii (NTS) of the brainstem (hind-
brain). In the hypothalamic arcuate nucleus (ARC), adi-
posity signal leptin influences expression of peptides
affecting food intake such as anorexigenic cocaine- and
amphetamine-regulated transcript (CART). ARC neurons
Published: 21 October 2008
BMC Neuroscience 2008, 9:101 doi:10.1186/1471-2202-9-101
Received: 27 May 2008
Accepted: 21 October 2008
This article is available from: http://www.biomedcentral.com/1471-2202/9/101
© 2008 Maletínská et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2008, 9:101 http://www.biomedcentral.com/1471-2202/9/101
Page 2 of 11
(page number not for citation purposes)
project to other hypothalamic areas such as the paraven-
tricular nucleus (PVN) and the lateral hypothalamic area
(LHA) (for reviews, see [1-5]). Both PVN and LHA convey
neuronal signals to the brainstem where they are inte-
grated with afferent input of cholecystokinin (CCK) [2],
satiety peptide of gut origin. For the satiety effect of CCK,
leptin signaling in ARC was found necessary [6]. Recently,
CCK was shown to facilitate access of leptin to hypotha-
lamic areas and modulate body weight [7].
Satiety effect of CCK is mediated by cholecystokinin A
(CCK-A or CCK-1) receptors [8] expressed abundantly not
only in the brainstem but also in the hypothalamus
[9,10]. Unlike CCK receptors, receptors of CART peptide
have not been found yet despite of a well-known anorex-
igenic effect of CART [3,11,12] and its stimulating effect
on anxiety-like reactions [13] or analgesia [14]. Analo-
gously, CART receptor antagonists have not been designed
yet.
After its peripheral administration, CCK affected neuronal
activity particularly in NTS, the area postrema, the locus
coeruleus, PVN, and the dorsomedial nucleus (DMH)
[5,15-18]. Similarly, injection of the CART peptide either
into the third, fourth, or the lateral ventricle suppressed
food intake [11,12,14,19,20] and stimulated expression
of c-Fos in NTS, the parabranchial nucleus, PVN and
DMH [21,22].
Co-localization of CART peptide and CCK-A receptor in
vagal afferent neurons suggested that CART peptide might
take part in mediating satiety effects of cholecystokinin
[23]. Interestingly, a lowered leptin level after 48- hour
food deprivation affected expression neither of CCK-A
receptor [23] nor CART in nodose ganglion neurons [24].
However, recently, CART expression in rat vagal afferent
neurons was found negligible after 24-hour fasting, up-
regulated by CCK, and restored after re-feeding. The
action of CCK on CART expression was shown to be medi-
ated by activation of protein kinase C and cAMP response
element binding protein (CREB) and was inhibited by
orexigenic ghrelin [25].
Relationship between CCK and the CART peptide was
documented also at pancreatic exocrine secretion of amy-
lase where the stimulating effect of CART peptide was
inhibited in vivo but not in vitro by CCK-A receptor antag-
onist devazepide [26].
Finally, a synergistic anorexigenic effect of CCK and CART
peptide was suggested in goldfish [27], but no experimen-
tal details were given.
Data on interaction of CART peptide with other peptides
regulating food intake have been scarce up to now.
Besides the well-known suppression of the orexigenic
effect of NPY by CART peptide [11,28], CART peptide-
induced hypophagia and brain c-Fos expression was pre-
vented by blocking central receptors for glucagon-like
peptide 1 (GLP-1) [29].
The previously described findings point to a neurochemi-
cal link between CART peptide and CCK with regard to a
previously found synergistic effect of leptin and CCK on
food intake [15]. Therefore, in the present study, the idea
is proposed that a co-operative action of the CART peptide
and CCK might be involved in communication between
ARC and NTS. Potential cooperation between central
CART peptide and peripheral CCK in the short-term regu-
lation of food intake in lean mice was investigated. To
compare neuronal activation after administration of
CART peptide, CCK, or simultaneous administration of
CART peptide and CCK, c-Fos activation in three impor-
tant brain areas involved in food intake regulation, PVN,
DMH, and NTS, was also determined. In addition, the
exploratory behavior of mice after administration of the
above-mentioned compounds is described, which is an
important element complementing food intake data.
Methods
Materials
Cholecystokinin octapeptide (CCK-8, Asp-Tyr(SO3H)-
Met-Gly-Trp-Met-Asp-Phe-NH2, NeoMPS, Strasbourg,
France), CCK-A receptor antagonist devazepide
(L364,718) or CCK-B receptor antagonist L365,260 (gift
from ML Laboratories, Liverpool, UK) and CART(61-102)
(Bachem, Bubendorf, Switzerland) were used in the exper-
iments.
The Fos (No 94012) antiserum was kindly provided by
Dr. J.D. Mikkelsen (NeuroSearch A/S Ballerup, Denmark).
The specificity and sensitivity of Fos antiserum have
already been tested previously [30].
Experimental animals
Male C57BL/6 mice obtained from the Institute of Molec-
ular Genetics (Prague, Czech Republic) were housed in
standard conditions (temperature of 23°C, daily cycle of
12 h light and dark (light from 6:00)). They were given ad
libitum water and standard chow diet (St-1, Velaz, Koleè,
Czech Republic). They were 14–16 weeks old (25–30 g)
when cannulation and following experiments were per-
formed. All experiments followed the ethical guidelines
for animal experiments and the Act of the Czech Republic
Nr. 246/1992 and were approved by the Committee for
experiments with laboratory animals of the Academy of
Sciences of the Czech Republic.BMC Neuroscience 2008, 9:101 http://www.biomedcentral.com/1471-2202/9/101
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Cannula placement
Mice were implanted with cannulas (Plastics One,
Roanoke, USA) into the third ventricle (AP 2 mm, V 3
mm) as described earlier [31]. Thereafter, the animals
were placed into separate cages with free access to food
and water and allowed to recover from surgery at least
seven days before starting the experiment.
Food intake experiments
Before starting the food intake experiment, the mice were
randomly divided into groups of 6–8 mice and were
fasted overnight (17 h) with free access to water.
On the day of the experiment, the individual groups of
mice underwent the following treatments before being
given weighed food (at t = 0 around 8:30) and the regis-
tration of food intake started.
Experiment 1 Individual and combined administration of CCK-8 and 
CART(61-102)
Doses, route of administration and time schedule are
described in Table 1.
Experiment 2 Individual and combined administration of CCK 
receptor antagonists and CART(61-102)
Doses, route of administration and time schedule are
described in Table 1.
The volume of i.p. injected solutions was 0.2 ml/mouse,
i.c.v. injected solutions were of 5 μl/mouse and were
infused in 20 s using an infusion pump; the infusion can-
nula was left in place for a further 20 s to prevent reflux.
Each animal was used only once, the experiment was
repeated with a new set of mice.
At t = 0 min, i.e. 15 min after i.c.v. injection of CART(61-
102) or 20 min after i.p. injected CCK-8 and 45 min after
i.p. injection of devazepide or L365,260, mice were given
weighed food pellets. The pellets were replaced with fresh
ones every 30 min and weighed. Food intake was followed
for 5 h. Animals had free access to water during the exper-
iment. The results are expressed in grams of food con-
sumed per mouse. The placement of the cannula was
verified histologically.
Fos Immunohistochemistry
Tissue processing
For Fos immunohistochemical processing, overnight
fasted mice (n = 5 mice/group) were treated: a/i.c.v. with
saline, b/i.p. with CCK-8 (0.4 μg/kg), c/i.c.v. with
CART(61-102) (0.1 μg/mouse) or d/i.p. with CCK-8 fol-
lowed by i.c.v. injected CART(61-102) (doses as described
above). The time schedule of injections was identical as in
the food intake study (Table 1). Sixty minutes after i.c.v.
injection, the mice were deeply anesthetized with pento-
barbital (50 mg/kg, i.p.) and perfused transcardially with
0.1 M phosphate buffer (PB, pH 7.4) containing 4% para-
formaldehyde, 0.1% glutaraldehyde, and 10% picric acid
(w/w). Then the brains were removed, postfixed in the
same fixative overnight at 4°C, and infiltrated with 30%
Table 1: Administration of compounds in mice, in food intake Experiment 1 and 2
Experiment 1
Compound Dose
i.p.
Time of application Compound Dose
i.c.v.
Time of application No. animals
saline -20 min 8
CCK-8 0.4 μg/kg -20 min 6
4- 2 0  m i n 6
saline -15 min 8
CART 0.1 μg/mouse -15 min 6
0.5 -15 min 6
CCK-8 0.4 μg/kg -20 min CART 0.1 μg/mouse -15 min 6
4- 2 0  m i n 0 . 1 - 1 5  m i n 6
0.4 μg/kg -20 min 0.5 μg/mouse -15 min 6
4- 2 0  m i n 0 . 5 - 1 5  m i n 7
Experiment 2
devazepide 1 mg/kg -45 min 6
1 -45 min CART 0.1 μg/mouse -15 min 6
1- 4 5  m i n 0 . 5 - 1 5  m i n 6
L365,260 1 mg/kg -45 min 6
1- 4 5  m i n 0 . 5 - 1 5  m i n 7
At time = 0 min, mice were given weighed food pellets.BMC Neuroscience 2008, 9:101 http://www.biomedcentral.com/1471-2202/9/101
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sucrose in 0.1 M PB for 48 h at 4°C. Before sectioning, the
brains were rapidly (20 sec) frozen in cold isopentane (-
30/-40°C) and placed into a Reichert cryocut device
adjusted to -16°C for 1 h. Location of i.c.v. cannulas in the
third ventricle was verified during sectioning and 30 μm
coronal sections were cut from the brains and collected as
free floating in cold (4°C) PB.
Immunohistochemistry
Free floating sections were repeatedly washed in cold PB
followed by preincubation in 3% H2O2 for 40 min at
room temperature. They were incubated with polyclonal
Fos protein antiserum (1:2000), diluted in 0.1 M PB con-
taining 4% normal goat serum (Gibco, Grand Island, NY,
USA), 0.5% Triton X-100 (Koch-Light Lab. Ltd., Col-
nbrook, Berks, England), and 0.1% sodium azide for 48 h
at 4°C. After several rinses in PB, the sections were incu-
bated with biotinylated goat-anti-rabbit IgG (1:500, Vec-
torStain Elite ABC, Vector Lab., Burlingame, CA, USA) for
90 min at room temperature. Next PB rinses were fol-
lowed by incubation with the avidin-biotin peroxidase
complex (1:250) for 90 min at room temperature. PB
washing was followed by washing in 0.05 M sodium ace-
tate buffer (SAB, pH 6.0). The Fos antigenic sites were vis-
ualized with 0.0266% 3,3'-diaminobenzidine
tetrahydrochloride (DAB) dissolved in SAB containing
0.0042% H2O2 and 2.5% nickel ammonium sulfate, for 7
min. The metal-intensification of DAB produced black
staining in the labeled nuclei. Finally, the sections were
rinsed in 0.05 M SAB, mounted into 0.1% of gelatine dis-
solved in 0.0125 M SAB, air-dried and coverslipped with
Permount (Sigma, St. Louis, MO, USA). Immunostaining
of negative control, which did not show any antiserum
immunolabeling, included substitution of the primary
antiserum with normal rabbit serum, and sequential elim-
ination of the primary or secondary antibody from the
staining series.
Evaluation of the immunostaining
An identical set of mice was used for determination of Fos
immunoreactivity in NTS, PVN, and DMH. Counting of
Fos immunoreactive cells within the NTS, from Bregma -
7.48 mm to Bregma -7.32 mm, PVN, from Bregma -0.7
mm to -0.94 mm, and DMH, from Bregma -1.46 mm to –
1.82 mm according to the mouse brain atlas [32], was per-
formed separately in each side of the sections. Quantita-
tive assessment was performed from the images captured
with a Canon digital camera (PowerShot S40) and Leica
DMLS light microscope in a computer screen obtained
from 5–6 brain sections per animal. Representative sec-
tions were captured by the same computerized system.
The counting of Fos-positive neurons was done by one of
the authors under blinded conditions (the counted slides
from each animal were analyzed independently and ran-
domly and encoded by other person).
Open field locomotor activity
Locomotor activity was measured using the VideoMot sys-
tem (TSE Systems, Bad Homburg, Germany). Ad libitum
fed mice were placed individually in the open field (1 × 1
m) and their locomotor activity, i.e. total distance
traveled, was measured for 10 min. Mice were adminis-
tered with i.p. injection of CCK-8 (4 μg/kg), i.p. injection
of devazepide (1 mg/kg), i.c.v. administration of
CART(61-102) (0.1 and 0.5 μg/mouse) or their combina-
tion with a time schedule as described in feeding experi-
ments in Table 1 (n = 5 mice/group).
Statistics
Data are presented as means ± SEM for the number of ani-
mals indicated in the Figures. They were analyzed by the
non-repeated measures one-way analysis of variance
(ANOVA) followed by Bonferroni post hoc test using
Graph-Pad Software (San Diego, CA, USA). P < 0.05 was
considered statistically significant.
Results
Synergistic action of CART peptide and CCK-8 in food 
intake of fasted lean mice
Experiment 1
Cumulative food intake of male C57BL/6 mice was meas-
ured for all doses of compounds described in Methods
(Table 1) and is illustrated by curves in Fig. 1. The feeding
response to saIine injected i.p. or i.c.v. did not show any
significant difference.
CART(61-102) at a dose of 0.5 μg/mouse significantly
attenuated food intake up to 105 min after its i.c.v. injec-
tion with maximum between 45 and 75 min after i.c.v.
injection, i.e. after the first and second measurements of
food intake (Fig. 1). A dose-dependent anorexigenic effect
of CART(61-102) is obvious in Fig. 2a. In C57BL/6 fasted
mice, CCK-8 doses of 0.4 and 4 μg/kg i.p. did not signifi-
cantly modify food intake (Fig. 2a).
Simultaneous application of CCK-8 and CART(61-102)
reduced food intake more significantly than each single
peptide (Fig. 1, 2a), and the effect lasted for more than five
hours (Fig. 1). Doses of CCK-8 (0.4 and 4 μg/kg)
increased the anorexigenic effect of CART(61-102) in a
dose-related way (Fig. 2a). Table 2 summarizes values of
food intake at the time of maximal effect of administered
peptides (30 minutes after addition of pellets).
Experiment 2
CCK-A receptor inactivation with its antagonist devazep-
ide prevented the anorexigenic effect of CART(61-102)
(0.1 and 0.5 μg/mouse), whereas the specific CCK-B
receptor antagonist L-365,260 did not affect the CART-
induced decrease in food intake (Fig. 2b, Table 2).BMC Neuroscience 2008, 9:101 http://www.biomedcentral.com/1471-2202/9/101
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Fos immunoreactivity in NTS, PVN, and DMH after CART 
peptide and CCK administration
The doses of CCK-8 (4 μg/kg) and CART(61-102) (0.1 μg/
mouse) used by us for determination of Fos immunoreac-
tivity correspond to those used previously by others
[18,19,30]. Statistical analysis by one way ANOVA docu-
mented the impact of CCK-8, CART(61-102) as well as
their combined treatment on the number of Fos immuno-
positive cells both in NTS (F3,16 = 26.23, p < 0.000001),
PVN (F3,13 = 100.35, p < 0.000001), and DMH (F3.12 =
58.19, p < 0.000001) in lean C57BL/6 mice (Fig. 3).
In NTS, the Fos immunoreactivity in saline-treated con-
trols was minimal and sporadic (Fig. 3a). The number of
Fos immunoreactive cells distinctly increased after i.p.
application of CCK-8 (0.4 μg/kg) compared with saline-
treated mice (P < 0.05) (Fig. 3a, d). A similar, but statisti-
cally insignificant increase was observed after i.c.v. infu-
sion of CART(61-102) (0.1 μg/mouse). The post hoc test
showed a significant effect (P < 0.01) of parallel adminis-
tration of CCK-8 and CART peptide on the Fos activation
of cells in NTS in comparison with all other groups of ani-
mals (Fig. 3a, d).
In PVN and DMH, Fos immunoreactivity followed a sim-
ilar trend as in the NTS. In control animals, a weak Fos sig-
nal was found (Fig. 3b,c). A significant increase in Fos
immunoreactivity was registered after application of CCK-
8 (p < 0.01), CART(61-102) (p < 0.01), and parallel
administration of CCK-8 and CART(61-102) (p < 0.01) in
comparison with saline-treated mice (Fig. 3b, d). The post
hoc  test revealed a significantly higher increase in the
number of Fos-immunopositive cells in PVN and DMH
after CART(61-102) application compared with applica-
tion of CCK-8 (Fig. 3b, c); simultaneous application of the
above-mentioned peptides (p < 0.01) activated Fos in
PVN and DMH more significantly than each particular
peptide alone (p < 0.01).
Cumulative food intake of 17-h fasted mice after administration of CCK-8 (0.4 μg/kg, i.p.), devazepide (1 mg/kg, i.p.) or after  administration of saline (i.c.v.), CART(61-102) (0.5 μg/mouse, i.c.v.), CCK-8 (0.4 μg/kg, i.p.) followed by CART(61-102) (0.5 μg/ mouse, i.c.v.), and devazepide (1 mg/kg, i.p.) followed by CART(61-102) (0.5 μg/mouse, i.c.v.) Figure 1
Cumulative food intake of 17-h fasted mice after administration of CCK-8 (0.4 μg/kg, i.p.), devazepide (1 mg/kg, i.p.) or 
after administration of saline (i.c.v.), CART(61-102) (0.5 μg/mouse, i.c.v.), CCK-8 (0.4 μg/kg, i.p.) followed by CART(61-102) 
(0.5 μg/mouse, i.c.v.), and devazepide (1 mg/kg, i.p.) followed by CART(61-102) (0.5 μg/mouse, i.c.v.). At time 0, weighed food 
was given to mice. Food intake is expressed in grams of food consumed (n = 6–8 mice per group). ** P < 0.01 vs. saline-treated 
group [ANOVA, F4,39 = 5.92].
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Dose-related inhibition of food intake in 17-h fasted mice after administration of Figure 2
Dose-related inhibition of food intake in 17-h fasted mice after administration of: A/ CCK-8 (0.4 and 4 μg/kg, i.p.) or i.c.v. 
saline, CART(61-102) (0.1 and 0.5 μg/mouse, i.c.v.), CCK-8 (0.4 and 4 μg/kg, i.p.) plus CART(61-102) (0.1 and 0.5 μg/mouse, 
i.c.v.), or B/ i.p. devazepide (1 mg/kg) alone or followed by i.c.v. CART(61-102) (0.1 and 0.5 μg/mouse) and i.p. L365,260 (1 mg/
kg) alone or followed by i.c.v. CART(61-102) (0.5 μg/mouse). Food intake is expressed in grams of food consumed in the first 
30 min after presentation of food (n = 6–8 mice per group). ** P < 0.01, *** P < 0.001 vs. saline-treated group, + P < 0.05 vs. 
CART(61-102) 0.1 μg/mouse, ++ P < 0.05 vs. CART(61-102) 0.5 μg/mouse [ANOVA, F12,78 = 13.88]. CART – CART(61-102), 
dev – devazepide, L365 – L365,260.
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Behavioral effect after parallel CART peptide and CCK-8 
injection
Open field locomotor activity of fed lean mice was meas-
ured for 10 min after i.c.v. administration of CART(61-
102), i.p. administration of CCK-8 and devazepide or
their combination (see Methods). The goal was to find out
whether in behavioral tests, the additive effect of CART
peptide and CCK-8 occurred similarly as in the food
intake experiments. The results clearly showed (Fig. 4)
that the CART peptide (0.5 μg/mouse) alone or in combi-
nation with CCK-8 (4 μg/kg) significantly shortened the
distance traveled in the open field compared to that of the
saline-treated group. The decrease of locomotor activity
after CART peptide treatment was reversed by CCK-A
antagonist devazepide (Fig. 4).
Discussion
In this study, the effect of simultaneous administration of
CART peptide and CCK on food intake, Fos immunoreac-
tivity in NTS, PVN, and DMH and locomotor activity
points to a positive cooperation between the CART pep-
tide and CCK.
Intracerebroventricular injections of CART(61-102) into
the third ventricle of fasted C57BL/6 mice attenuated food
intake (Fig. 1, 2) in a dose-dependent manner similarly as
in the studies of Thim et al. [12], Bannon et al. [14] and
Vrang et al. [22]. At the doses of 0.4 and 4 μg/kg, CCK-8
did not show any significant effect on food intake in
fasted C57BL/6 mice (Fig. 2a) (with EC50 about 15 μg/kg
determined in a preliminary study), unlike fasted outbred
NMRI mice that were sensitive to CCK-8 dose of 4 μg/kg
(with EC50 about 9 μg/kg [31]). Serum leptin after 17 h
fasting was 50% higher in the robust NMRI mice com-
pared to the subtle C57BL/6 mice (0.45 ± 0.14 ng/ml in
NMRI [33] and 0.30 ± 0.06 ng/ml in C57BL/6 male mice,
our non-published data), which was probably the reason
why the threshold dose for CCK-8 was higher in C57BL/6
than in NMRI mice (4 versus 0.4 μg/kg, respectively).
The 48-hour long fasting was shown to attenuate the sati-
ety response to CCK because of a lowered leptin level [34].
Barrachina et al. [15] demonstrated that leptin cooperated
synergistically with satiety effect of CCK in 24-hour fasted
C57BL/6 mice [15]. Therefore in this study, it is supposed
that synergistic co-operation of leptin and CCK was pre-
served in 17- hour fasted C57BL/6 mice despite lowered
leptin level after fasting.
In this study, low doses of CCK enhanced the anorexi-
genic effect of CART peptide in a dose-dependent way and
prolonged the time of the CART peptide effect (Fig. 1) that
was in agreement with our hypothesis on a synergistic
effect of CART(61-102) and CCK-8 on food intake (Fig.
2a). A direct involvement of CCK-A receptor in the ano-
rexigenic effect of CART peptide was demonstrated in this
study, because selective CCK-A receptor antagonist
devazepide [8] was found to block the effect of CART pep-
tide on food intake (Fig. 2b). Similarly, the anorexigenic
action of CART peptide in rats was prevented by GLP-1
receptor antagonist [29]. The fact that L365,260, selective
CCK-B receptor antagonist, which is not involved in food
Table 2: Food intake of 17-h fasted mice during first 30 min measured (maximal effect) in Experiment 1 and 2
Compound/dose Food intake/30 min
(g ± SEM)
i.p. i.c.v.
saline 0.77 ± 0.06
saline 0.73 ± 0.07
CCK-8 0.4 μg/kg 0.80 ± 0.13
4 0.60 ± 0.09
CART 0.1 μg/mouse 0.54 ± 0.04 **
0.5 0.40 ± 0.07 ***
CCK-8 0.4 μg/kg CART 0.1 μg/mouse 0.45 ± 0.13 **
4 0.1 0.24 ± 0.03 *** +
CCK-8 0.4 μg/kg CART 0.5 μg/mouse 0.22 ± 0.02 ***
4 0.5 0.08 ± 0.01 *** ++
devazepide 1 mg/kg 0.93 ± 0.05
1 CART 0.1 μg/mouse 0.65 ± 0.11
1 0.5 0.69 ± 0.08
L365,260 1 0.79 ± 0.05
1 0.5 0.34 ± 0.01 ***
**P < 0.01, ***P < 0.001 versus saline-treated group. +P < 0.05 versus group treated by CART, 0.1 μg/mouse, ++ P < 0.01 versus group treated by 
CART, 0.5 μg/mouse.BMC Neuroscience 2008, 9:101 http://www.biomedcentral.com/1471-2202/9/101
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Fos immunoreactivity Figure 3
Fos immunoreactivity: Fos-immunostained cells in coronal section of A/ NTS, B/ PVN, C/ DMH, D/ Number of Fos-immu-
nopositive cells in NTS, PVN and DMH 60 minutes after i.c.v. application of saline (SAL), CCK-8 (4 μg/kg, i.p.), CART(61-102) 
(0.1 μg/mouse, i.c.v.), and their combination expressed unilaterally per animal (n = 4–5) and section (n = 5–6). + P < 0.01 vs. 
SAL, CCK and CART, * P < 0.05, ** P < 0.01 vs. SAL [ANOVA, for NTS F3,16 = 26.23, for PVN F3,13 = 100.35, for DMH F3,12 = 
58.19]. SAL – saline, NTS – solitary tract nucleus, CC – central canal, AP – area postrema, PVN – paraventricular nucleus. Bar 
= 100 μm.BMC Neuroscience 2008, 9:101 http://www.biomedcentral.com/1471-2202/9/101
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intake regulation [8], did not alter the decrease in food
intake induced by the CART peptide (Fig. 2b) supported
the idea of the involvement of exclusively CCK-A receptor
type in its co-operation with the CART peptide.
Co-administration leptin with CCK-8 in a dose of 3.5 μg/
kg i.p. that was considered subthreshold potentiated sati-
ety and activation of brainstem neurons in lean C57BL/6
mice and also enhanced the number of Fos-positive neu-
rons in PVN [15]. In this study, the Fos immunoreactivity
after injection of the CART peptide or/and CCK-8 was
determined in NTS, PVN, and DMH, common targets of
CART peptide [21,22] and CCK [5,15-18], in the identical
set of mice. A strong increase in the number of Fos-posi-
tive cells was found (Fig. 3) when the dose of CART pep-
tide that significantly attenuated food intake was co-
administered with a dose of CCK-8 that did not influence
food intake; this response was more significant than the
response to each particular peptide. This result confirmed
the co-operation between the CART peptide and CCK-8 in
the brainstem and hypothalamic PVN and DMH, where
satiety signals originating in the periphery as well as in the
forebrain are processed. PVN is highly innervated by affer-
ent projections from DMH. It was shown that CCK might
activate corticotropin-releasing factor (CRF) neurons in
DMH [18] via noradrenergic projections from NTS [35].
This pathway could contribute to the additive effect of
CCK and CART peptide in the DMH.
Finally, behavioral data followed the trend of the feeding
tests. CART peptides are known to influence locomotor
activity and analgesia [13,14]. However, the significance
of the effects differed in different studies. In this study, a
dose of CCK-8 that did not attenuate food intake (4 μg/kg
i.p.) did not also significantly lower the locomotor activity
of C57BL/6 mice in the open field test (Fig. 4), while
CART(61-102) at a dose of 0.5 μg/mouse and its combi-
nation with CCK-8 significantly suppressed the distance
traveled in open field test. Analogously, devazepide alone
did not significantly affect the locomotor activity of mice
compared to the saline-treated group but blocked the
effect of CART peptide (Fig. 4). These findings again sug-
gest that the effect of CART peptide was pronounced
through activation of CCK-A receptor and point to satiety-
related sedation. Analgesic hot-plate test was also per-
formed, but none of the above-mentioned compounds
Behavioral activity of fed mice (open field test, total distance traveled for 10 min) after i.p. administration of CCK-8 (4 μg/kg)  or devazepide (1 mg/kg), after i.c.v. administration of saline, CART(61-102) (0.1 and 0.5 μg/mouse), or after combined injection  of i.p. CCK-8 or devazepide followed by i.c.v. CART(61-102) Figure 4
Behavioral activity of fed mice (open field test, total distance traveled for 10 min) after i.p. administration of CCK-8 (4 μg/
kg) or devazepide (1 mg/kg), after i.c.v. administration of saline, CART(61-102) (0.1 and 0.5 μg/mouse), or after combined 
injection of i.p. CCK-8 or devazepide followed by i.c.v. CART(61-102). ** P < 0.01 vs. saline-treated group [ANOVA, F6,38 = 
6.29]. CART – CART(61-102), dev – devazepide, L365 – L365,260.
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significantly changed the paw-licking latency compared to
the saline-treated group (data not shown).
The long lasting effect of synergistic action of CCK and the
CART peptide in this study could be interpreted according
to de Lartigue et al. [25] as a result of CCK- induced expres-
sion of CART and a consequent effect of the endogenously
produced CART peptide after the exogenous CART pep-
tide was exhausted. On the other hand, Broberger et al.
described that expression of CCK-A receptor does not
depend on the metabolic status [23].
The integratory role of the ARC-PVN-DVC (dorsal vagal
complex in which NTS is included) was suggested for the
synergistic action of leptin and CCK on the attenuation of
food intake and body weight [15]. Food intake was
affected by parallel administration of leptin and CCK
more potently than by individual application of the hor-
mones and lasted at least 7 h. Leptin and CCK activation
pathways appeared to overlap at three discrete nuclei: the
PVN, parabrachial nucleus and NTS [5].
Conclusion
In this study, the synergistic effect of CCK and CART pep-
tide on food intake targeted hypothalamic PVN and DMH
and NTS, which suggested that CART peptide might act as
a mediator of the leptin anorexigenic effect both in the
hypothalamus and brainstem. Identification of the CART
peptide receptor and designing its antagonist is necessary
for identification of further possible cooperative actions
of the CART peptide.
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